Chinen et al., 2014 - Google Patents
The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy‐related acute myeloid leukemia with t (8; …Chinen et al., 2014
- Document ID
- 11809672183068248579
- Author
- Chinen Y
- Taki T
- Tsutsumi Y
- Kobayashi S
- Matsumoto Y
- Sakamoto N
- Kuroda J
- Horiike S
- Nishida K
- Ohno H
- Uike N
- Taniwaki M
- Publication year
- Publication venue
- Genes, Chromosomes and Cancer
External Links
Snippet
The monocytic leukemia zinc finger protein KAT6A (formerly MOZ) gene is recurrently rearranged by chromosomal translocations in acute myeloid leukemia (AML). KAT6A is known to be fused to several genes, all of which have histone acetyltransferase (HAT) …
- 101700031977 LEUTX 0 title abstract description 60
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Quessada et al. | Cytogenetics of pediatric acute myeloid leukemia: a review of the current knowledge | |
| Chinen et al. | The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy‐related acute myeloid leukemia with t (8; 19)(p11; q13) | |
| Deniz et al. | Endogenous retroviruses are a source of enhancers with oncogenic potential in acute myeloid leukaemia | |
| Huang et al. | Novel FUS‐KLF17 and EWSR1‐KLF17 fusions in myoepithelial tumors | |
| Rowley et al. | All patients with the T (11; 16)(q23; p13. 3) that involves MLL and CBP have treatment-related hematologic disorders | |
| Postel-Vinay et al. | Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma | |
| Pabst et al. | Complexity of CEBPA dysregulation in human acute myeloid leukemia | |
| Karlsson et al. | Activation of human telomerase reverse transcriptase through gene fusion in clear cell sarcoma of the kidney | |
| Yildiz et al. | Activating STAT6 mutations in follicular lymphoma | |
| Ryan et al. | Detection of enhancer-associated rearrangements reveals mechanisms of oncogene dysregulation in B-cell lymphoma | |
| Russler-Germain et al. | The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers | |
| Yokoyama et al. | A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription | |
| Borkhardt et al. | The human GRAF gene is fused to MLL in a unique t (5; 11)(q31; q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q | |
| Chen et al. | The t (1; 3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas | |
| von Bergh et al. | High incidence of t (7; 12)(q36; p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9 | |
| Loke et al. | RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t (8; 21) and t (3; 21) AML | |
| Aihara et al. | Cloning and mapping of SMARCA5 encoding hSNF2H, a novel human homologue of Drosophila ISWI | |
| Panuzzo et al. | Landscape of tumor suppressor mutations in acute myeloid leukemia | |
| Naramura et al. | Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders | |
| Alvarez Argote et al. | ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival | |
| Abbas et al. | Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations | |
| Panagopoulos et al. | Recurrent fusion of the genes for high-mobility group AT-hook 2 (HMGA2) and nuclear receptor co-repressor 2 (NCOR2) in osteoclastic giant cell-rich tumors of bone | |
| Giguère et al. | Microhomologies and topoisomerase II consensus sequences identified near the breakpoint junctions of the recurrent t (7; 21)(p22; q22) translocation in acute myeloid leukemia | |
| González-Gil et al. | The Yin and Yang-like clinical implications of the CDKN2A/ARF/CDKN2B gene cluster in acute lymphoblastic leukemia | |
| Kaczmarska et al. | The landscape of secondary genetic rearrangements in pediatric patients with B-cell acute lymphoblastic leukemia with t (12; 21) |